Výsledky vyhledávání - "Ravi A Madan"

Akademický článek

First-in-human, phase 1 study of PF-06753512, a vaccine-based immunotherapy regimen (VBIR), in non-metastatic hormone-sensitive biochemical recurrence and metastatic castration-resistant prostate cancer (mCRPC)

Publikováno v: Journal for ImmunoTherapy of Cancer, Vol 11, Iss 3 (2023)

Background This phase 1 study evaluated PF-06753512, a vaccine-based immunotherapy regimen (PrCa VBIR), in two clinical states of prostate cancer (PC), metastatic castration-resistant PC (mCRPC) and biochemical recurrence (BCR).Methods For dose escal

Externí odkaz: https://doaj.org/article/a4a8a3a078ab4567a1641ae4c2b5d1db

Zobrazit plný text záznamu

Akademický článek

Phase I study of a multitargeted recombinant Ad5 PSA/MUC-1/brachyury-based immunotherapy vaccine in patients with metastatic castration-resistant prostate cancer (mCRPC)

Autor: Renee N Donahue, Jeffrey Schlom, James L Gulley, Ravi A Madan, Claudia Palena, Caroline Jochems, Shahrooz Rabizadeh, Patrick Soon-Shiong, Sheri McMahon, Julius Strauss, Marijo Bilusic, Fatima Karzai, Houssein Abdul Sater, Jennifer L Marté, Yo-Ting Tsai, Jason Redman, Charalampos Floudas

Publikováno v: Journal for ImmunoTherapy of Cancer, Vol 9, Iss 3 (2021)

Background Antitumor vaccines targeting tumor-associated antigens (TAAs) can generate antitumor immune response. A novel vaccine platform using adenovirus 5 (Ad5) vectors [E1–, E2b–] targeting three TAAs—prostate-specific antigen (PSA), brachyu

Externí odkaz: https://doaj.org/article/0ba9e720c5394549bc0af34acac98f93

Zobrazit plný text záznamu

Akademický článek

Bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in patients with human papillomavirus-associated malignancies

Publikováno v: Journal for ImmunoTherapy of Cancer, Vol 8, Iss 2 (2020)

Background Bintrafusp alfa is a first-in-class bifunctional fusion protein composed of the extracellular domain of transforming growth factor (TGF)-βRII (a TGF-β ‘trap’) fused to a human IgG1 mAb blocking programmed cell death ligand 1. This is

Externí odkaz: https://doaj.org/article/8d0952dbd2c84693b0a6b1394990bc11

Zobrazit plný text záznamu

Akademický článek

Neoadjuvant PROSTVAC prior to radical prostatectomy enhances T-cell infiltration into the tumor immune microenvironment in men with prostate cancer

Autor: Renee N Donahue, Jeffrey Schlom, James L Gulley, Christopher R Heery, Ravi A Madan, Marijo Bilusic, Fatima Karzai, Houssein Abdul Sater, Jennifer L Marté, Beatriz Walter-Rodriguez, Seth M Steinberg, Guinevere Chun, Stephanie A Harmon, Ismail Baris Turkbey, Peter L Choyke, William L Dahut, Peter A Pinto

Publikováno v: Journal for ImmunoTherapy of Cancer, Vol 8, Iss 1 (2020)

Background Clinical trials have shown the ability of therapeutic vaccines to generate immune responses to tumor-associated antigens (TAAs). What is relatively less known is if this translates into immune-cell (IC) infiltration into the tumor microenv

Externí odkaz: https://doaj.org/article/8ceb7e3397a141ef99a929661525827a

Zobrazit plný text záznamu

Akademický článek

Perspectives on the clinical development of immunotherapy in prostate cancer

Autor: Lisa M Cordes, James L Gulley, Ravi A Madan

Publikováno v: Asian Journal of Andrology, Vol 20, Iss 3, Pp 253-259 (2018)

Despite impressive survival benefits with immunotherapy in patients with various solid tumors, the full potential of these agents in prostate cancer has yet to be realized. Sipuleucel-T demonstrated a survival benefit in this population, indicating t

Externí odkaz: https://doaj.org/article/a7cb5659a57a4cb2ae63185d45e14535

Zobrazit plný text záznamu

Akademický článek

The path forward in prostate cancer therapeutics

Autor: Jeanny B Aragon-Ching, Ravi A Madan

Publikováno v: Asian Journal of Andrology, Vol 20, Iss 3, Pp 213-214 (2018)

Externí odkaz: https://doaj.org/article/41585c1fb3a0421fb88d94b05fa7971a

Zobrazit plný text záznamu

Akademický článek

Phase I trial of HuMax-IL8 (BMS-986253), an anti-IL-8 monoclonal antibody, in patients with metastatic or unresectable solid tumors

Autor: Marijo Bilusic, Christopher R. Heery, Julie M. Collins, Renee N. Donahue, Claudia Palena, Ravi A. Madan, Fatima Karzai, Jennifer L. Marté, Julius Strauss, Margaret E. Gatti-Mays, Jeffrey Schlom, James L. Gulley

Publikováno v: Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1, Pp 1-8 (2019)

Abstract Background HuMax-IL8 (now known as BMS-986253) is a novel, fully human monoclonal antibody that inhibits interleukin-8 (IL-8), a chemokine that promotes tumor progression, immune escape, epithelial-mesenchymal transition, and recruitment of

Externí odkaz: https://doaj.org/article/df02368d4e9e4af5bd803ce31f37897d

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání